Catégorie : Cannabis et santé mentale

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington, Jeremy Mennis, Gerald J Stahler, 2020

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]

Lire la suite

Après la crise du Covid-19 il faut légaliser le cannabis, vite !, François-Michel LAMBERT député des Bouches du Rhône, 2020

Après la crise du Covid-19 il faut légaliser le cannabis, vite ! François-Michel LAMBERT député des Bouches du Rhône   En juin 2019 avec une vingtaine de députés nous déposions une proposition de loi, relative « à la légalisation contrôlée de la production, de la vente et de la consommation de cannabis ». La même semaine le « conseil d’analyse économique », think tank rattaché à Matignon, préconisait dans un rapport très documenté la légalisation du cannabis récréatif et une tribune dans l’Obs signée par 70 médecins, économistes et élus nationaux et locaux, plaidait pour cette légalisation. Ces initiatives pour la légalisation du cannabis dénoncent [...]

Lire la suite

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al., 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial, Daryl Efron et al.,

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams BMJ Open, 2020, 10, e034362. doi : 10.1136/bmjopen-2019-034362   Abstract Introduction : Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal [...]

Lire la suite

A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability, Daryl Efron et al., 2020

  A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams British Journal of Clinical Pharmacology, 2020 Jun 1. doi : 10.1111/bcp.14399. Abstract Introduction : Severe Behavioural Problems (SBP) are a major contributor to morbidity in children with Intellectual Disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled [...]

Lire la suite

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale, 18 novembre 2020

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale Affiche – 25es Rencontres RESPADD En raison de la situation sanitaire actuelle et pour préserver la santé de chacun, le RESPADD a décidé de reporter ses 25es Rencontres. NOUVELLE DATE : le 18 novembre 2020 Les 25es Rencontres professionnelles du RESPADD, réalisées en partenariat avec le Groupement addictions Franche-Comté, la Société psychédélique française et le CHS Saint-Ylie Jura, se tiendront le mercredi 18 novembre 2020 à la Commanderie de Dole. Cette nouvelle édition des Rencontres du RESPADD explorera les nouveaux usages des drogues en santé mentale et [...]

Lire la suite

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, Barbara Broers et al., 2019

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]

Lire la suite

The 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis 2019), Barcelona, Spain, May 23–24, 2019

The 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis 2019) Barcelona, Spain, May 23–24, 2019   Abstracts Congress Chairs: Prof. Dr. Med. Winfried Häuser, Klinikum Saarbrücken, Germany Dr. Silviu Brill, Tel Aviv Medical Center, Israel Medical Cannabis & Cannabinoids, 2019, 2, 69–83 Published online: May 13, 2019 Doi : 10.1159/000500623 KRAGER : Basel · Freiburg · Paris · London · New York · Chennai · New Delhi · Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney © 2019 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca   P-01 Cannabis and Metals: Soils Need to be Controlled Yann Barguil , Laura Chiaradia Biochemistry and Toxicology Laboratory, Gaston Bourret Territorial Hospital [...]

Lire la suite

4th International Medical Cannabis Conference (CannX 2019), Tel Aviv, Israel, September 9–10, 2019

4th International Medical Cannabis Conference (CannX 2019) Tel Aviv, Israel, September 9–10, 2019   Abstracts Scientific Committee Dr. Adi Aran Director of the Neuro-Pediatric Unit, Shaare Zedek Medical Center, Israel Prof. Gil Bar-Sela Head, Cancer Center, Emek Medical Center Afula, Israel Dr. Nirit Bernstein Principle Research Scientist, Plant Physiology and Nutrition Institute of Soil Water and Environmental Sciences, Volcani Center, Israel Prof. Lumir Hanus Chief Scientist, Lumir Lab, Associate Professor, Palacký University, Jerusalem Biotechnology Park, Hebrew University, Ein Kerem Campus, Senior Fellow, IEHP, Thomas Jefferson University, Philadelphia, USA, Professor Chaver and Research Fellow, Hebrew University (Ret.) Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University, Israel Dr. Shaul Lev-Ran, MHA Deputy Director, Lev Hasharon Medical Center [...]

Lire la suite

Cannabis médical : que penser de la forme de désinvolture de nos «autorités de santé» ?, Jean-Yves NAU, Blog Le Monde, 4 juin 2020

Cannabis médical : que penser de la forme de désinvolture de nos «autorités de santé» ? 4 juin 2020 https://jeanyvesnau.com/2020/06/04/cannabis-medical-que-penser-de-la-forme-de-desinvolture-des-autorites-de-sante-francaises/ jeanyvesnau Douleur, Hôpital, Médecine, médicament, Polémique, Politique, Pouvoir, Risques (réduction des), Soigner Bonjour 04/03/2020. Sans doute faudrait-il faire un effort, comprendre les difficultés de l’instant, les agendas perturbés, les responsables trop occupés … On peut, aussi, dire qu’il y a, dans le dernier communiqué de l’Agence nationale de sécurité du médicament (ANSM), sur l’usage médical du cannabis , une forme de désinvolture que l’on peu tenir pour inacceptable vis-à-vis des malades concernés par le sujet. On lit ainsi : «  Dans la continuité des travaux menés depuis 2018, [...]

Lire la suite